Skip to content
Home/Companies/Healthcare/TransCure bioServices
TransCure bioServices

TransCure bioServices

Healthcare·France·Exited 2026·Held 4yr
Entry
2022
Hold
4yr
Exit
2026

Who owns TransCure bioServices?

TransCure bioServices was owned by Cathay Capital through Cathay Capital Midcap II (2020 vintage) from 2022 to 2026, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Cathay Capital
Investor
Cathay Capital
Cathay Capital Midcap II · 2020 · Buyout

Key facts

HQFrance
SectorHealthcare
Websitewww.transcurebioservices.com
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2026

More from Cathay Capital Midcap II

Other portfolio companies in the same fund.

Juliette has a Gun
Juliette has a Gun
Active
ConsumerChina· 2023
DiliTrust
DiliTrust
Active
SoftwareFrance· 2022
Mistine
Active
ConsumerChina· 2022
Shiro Games
Shiro Games
Active
ConsumerFrance· 2022
SNOCKS
Snocks
Active
ConsumerFrance· 2022
AD Education
Active
ConsumerFrance· 2021

More PE-backed in Healthcare

Comparable healthcare deals from other GPs.

3i – Implant Innovations Inc.
Active
Advent InternationalUS
A Place for Mom
A Place for Mom
Active
Silver LakeUS
Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
Abbisko Healthcare
Active
The Carlyle GroupChina
Abode Healthcare
Active
Summit PartnersUS
AccentCare
AccentCare
Active
Advent InternationalUS
Track TransCure bioServices

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on TransCure bioServices.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue